Agenus reports Phase 2 BOT+BAL melanoma trial shows 22% response rate

• Agenus disclosed first Phase 2 results from its C-800-23 study of botensilimab with balstilimab in advanced cutaneous melanoma that had progressed on prior checkpoint therapy; the full dataset is scheduled for presentation on May 31, 2026 at the ASCO annual meeting.
• The readout showed durable tumor responses in a heavily pretreated, checkpoint-refractory population, with survival results that compared favorably with published benchmarks in patients previously exposed to both PD-(L)1 and CTLA-4 therapy.
• Safety was in line with established CTLA-4 and PD-1 inhibitor profiles, with no new safety signals or treatment-related deaths reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260521169634) on May 21, 2026, and is solely responsible for the information contained therein.